This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vandenborre, K. Articles by Vandenberghe, P. Search for Related Content PubMed PubMed Citation Articles by Vandenborre, K. Articles by Vandenberghe, P.

American Journal of Pathology, Vol 152, 963-973, Copyright © 1998 by American Society for Investigative Pathology

REGULAR ARTICLES

Human CTLA-4 is expressed in situ on T lymphocytes in germinal centers, in cutaneous graft-versus-host disease, and in Hodgkin's disease

K Vandenborre, J Delabie, MA Boogaerts, R De Vos, K Lorre, C De Wolf-Peeters and P Vandenberghe
Laboratory for Experimental Hematology, University of Leuven, Belgium.

Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4, CD152) is a molecule expressed on in vitro activated T cells. CTLA-4 shares important sequence homology with CD28 and binds to the same ligands, CD80 (B7-1) and CD86 (B7-2). CTLA-4 probably functions as a negative regulator of T lymphocyte activation in the mouse, although this remains to be proven for human T lymphocytes. We have developed new monoclonal antibodies against human CTLA-4 and have investigated the in situ expression of CTLA-4 in a wide variety of normal and pathological human tissues expressing CD80 and CD86. As revealed in this study, CTLA- 4 is expressed on thymocytes in thymic medulla, on a subset of CD4+ T lymphocytes in germinal centers of follicular hyperplasia, on T cells, mainly CD8+, infiltrating skin affected by graft-versus-host disease, and on T cells, mainly CD4+, infiltrating Hodgkin's disease lesions. In immunoelectron microscopy, CTLA-4 was found on the plasma membrane as well as in the hyaloplasm and cytoplasmic vesicles, in agreement with its pattern of expression on in vitro activated T cells. Interestingly, no or at most scarce expression of CTLA-4 was found in granulomatous lymph nodes, T-cell-mediated inflammatory diseases, or non-Hodgkin's lymphomas, regardless of their expression of CD80 or CD86. Thus, expression of CTLA-4 appears to be induced in selective pathological conditions in vivo. The pathways leading to selective induction of CTLA- 4 and its role in the pathophysiology of these conditions need to be further investigated.

This article has been cited by other articles:

				K. Botturi, Y. Lacoeuille, P. Thomas, S. Boniface, M. Reynaud-Gaubert, and A. Magnan CTLA-4-mediated regulatory phenotype of T-cells in tolerant lung recipients Eur. Respir. J., June 1, 2008; 31(6): 1167 - 1176. [Abstract] [Full Text] [PDF]

				N. A. Marshall, L. E. Christie, L. R. Munro, D. J. Culligan, P. W. Johnston, R. N. Barker, and M. A. Vickers Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma Blood, March 1, 2004; 103(5): 1755 - 1762. [Abstract] [Full Text] [PDF]

				V. M. Jovasevic, L. Gorelik, J. A. Bluestone, and M. B. Mokyr Importance of IL-10 for CTLA-4-Mediated Inhibition of Tumor-Eradicating Immunity J. Immunol., February 1, 2004; 172(3): 1449 - 1454. [Abstract] [Full Text] [PDF]